

# Dapivirine Vaginal Ring: Path to Regulatory Approval

Leonard Solai, IPM
Microbicide Trials Network Regional Meeting
Cape Town

Developing HIV Prevention Products for Women worldwide

## Path to Regulatory Approval

### IPM's role: Dapivirine ring's regulatory sponsor

- Holds worldwide rights to dapivirine
- Ensure all preclinical, clinical and pharmaceutical quality/chemistry, manufacturing and controls (CMC) data meet regulatory requirements
- Formally apply for dapivirine ring approval through European, US and African regulatory authorities



Approval pathway for new HIV prevention drug can be more complex than for a drug already approved for treatment (e.g., oral Truvada)



## **Regulatory Submission Update**

European Medicines Agency (EMA)

- Scientific opinion via Article 58, (EC Regulation 726/2004)
- Submission: 22 June '17; CTD currently under review
- D80: Assessment report 30 Sep '17
- D120: Questions 9 Nov '17

World Health
Organization (WHO)



- Following WHO PQ, first tier of submissions to Kenya, Malawi, Rwanda, Tanzania, Uganda, Zambia and Zimbabwe
- Medicines Control Council (MCC, SA)
- Target submission Q1/2 2018

US Food and Drug Administration (FDA)  Target submission Q3/4 2018 WHO Prequalification (PQ)

#### **Observer Countries:**

- Kenya
- South Africa
- Tanzania

Essential Drug List





## Why WHO Prequalification?



 Process to evaluate whether a drug meets global standards

Quality, Safety, Efficacy

Many African regulatory agencies use WHO prequalification to determine which new products to approve, and review EMA decisions



## But why does it take so long?

For the dapivirine ring, IPM has organised 13 years of data and findings from nearly 250 studies into each application


- 260000 pages
- 1200 files
- 69000 links
- >10 hour to upload



Submission done by eCTD



## **Regulatory Timeline**







## We need strong partnerships

Women, End-Users, Communities





